Roche

Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death1 People with relapsed or refractory LBCL represent one of the highest unmet need populations in lymphoma and require timely access to effective therapies If approved, this outpatient-ready regimen could enable access to care in the community setting, where most US patients receive treatment Basel, June 18, 2026 - Roche...

The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments1 The FDA approval reinforces Roche’s leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomes...

Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone1 Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options2,3 If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H* colon cancer after surgery Basel, 11 June 2026 - Roche...

Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche’s oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton’s Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08...

Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy1 Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years1-3 Giredestrant has the potential to become a new standard-of-care in the adjuvant setting; more than 90% of ER-positive breast cancer cases are diagnosed at an early-stage (I-III)4-7 The FDA has...

We are pleased to invite investors and analysts to participate in our virtual event on Monday, 8 June 2026, to highlight the new data from the Phase II 103 study of enicepatide in obesity, as well as from the Phase II ZUPREME-1 study of petrelintide in obesity, which will be presented at the American Diabetes Association’s (ADA) Scientific Sessions from 05-08 June 2026.

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity A Phase II multi-arm trial...

Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO—a certified algorithm developed by the health tech company Evido—requiring only age and routine blood markers for the timely detection of liver fibrosis With CLD affecting 1.5 billion people worldwide, the non-invasive panel solution covers care along the patient pathway from fibrosis risk identification to the...

The Roche Investor Relations team would like to invite you to an analyst and investor event on Tuesday, 2 June 2026, to highlight Roche's late stage oncology pipeline with a special focus on giredestrant, at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (May 29 - June 2, 2026).

Medicine or molecule Abstract title Abstract number/ presentation details Breast cancer Giredestrant Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA Breast Cancer (BC) trial #LBA1006 oral Breast Cancer — Metastatic Tuesday 02 June 2026 11:45 - 11:57 AM CDT Giredestrant...